These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 11881433

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Erythropoietin resistance and survival in non-dialysis patients with stage 4-5 chronic kidney disease and heart disease.
    Guerrero-Riscos MÁ, Montes-Delgado R, Seda-Guzmán M, Praena-Fernández JM.
    Nefrologia; 2012 May 14; 32(3):343-52. PubMed ID: 22535158
    [Abstract] [Full Text] [Related]

  • 5. Effects of recombinant human erythropoietin on hematopoietic progenitors of chronic hemodialysis patients in vitro and in vivo.
    Hino M, Miyazono K, Urabe A, Takaku F.
    Int J Cell Cloning; 1989 Jul 14; 7(4):257-63. PubMed ID: 2768843
    [Abstract] [Full Text] [Related]

  • 6. Effects of withdrawing erythropoietin.
    Taylor JE, Henderson IS, Mactier RA, Stewart WK.
    BMJ; 1991 Feb 02; 302(6771):272-3. PubMed ID: 1998794
    [No Abstract] [Full Text] [Related]

  • 7. Secondary hyperparathyroidism as cause of resistance to treatment with erythropoietin: effect of parathyroidectomy.
    Goicoechea M, Gomez-Campdera F, Polo JR, Tejedor A, Ruiz MA, Vazquez I, Verde E, Valderrabano F.
    Clin Nephrol; 1996 Jun 02; 45(6):420-1. PubMed ID: 8793241
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Recombinant human erythropoietin (r-HuEPO): quality of life and other considerations.
    Tan A.
    J CANNT; 1990 Jun 02; ():13-4. PubMed ID: 2202375
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS.
    Transplant Proc; 1991 Apr 02; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract] [Full Text] [Related]

  • 14. [Erythropoietin in renal anemia].
    Peña Amaro MP, García López J, Camacho Romera M.
    Rev Enferm; 1992 Mar 02; 15(163):67-70. PubMed ID: 1565973
    [No Abstract] [Full Text] [Related]

  • 15. [Recombinant human erythropoietin and chronic kidney failure: current situation and therapeutic implications].
    Romero González R, Torquet Escuder P.
    Med Clin (Barc); 1990 Nov 17; 95(17):656-9. PubMed ID: 2089205
    [No Abstract] [Full Text] [Related]

  • 16. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A, McCrea JB.
    ASAIO J; 1993 Nov 17; 39(1):11-8. PubMed ID: 8439674
    [No Abstract] [Full Text] [Related]

  • 17. Sub-optimal doses of human recombinant erythropoietin markedly lower serum ferritin.
    Jones-Lecointe A, Green PJ, Lee HA.
    Clin Lab Haematol; 1991 Nov 17; 13(3):251-3. PubMed ID: 1794227
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Erythropoietin resistance].
    Branger B.
    Nephrologie; 2002 Nov 17; 23(1):3-5. PubMed ID: 11887576
    [No Abstract] [Full Text] [Related]

  • 20. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators.
    Clin Nephrol; 2007 May 17; 67(5):306-17. PubMed ID: 17542340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.